Triple-negative breast cancer (TNBC) has always been a challenge in clinical treatment due to its high heterogeneity, high risk of recurrence, and poor prognosis. For patients with first-line (1L) advanced TNBC who are not eligible for immune checkpoint inhibitors (PD-1/L1 inhibitors), the benefits of traditional single-agent chemotherapy are limited. The emergence of antibody-drug conjugates (ADCs) has brought new hope to this population. As the world's first approved ADC targeting Trop-2, Sacituzumab Govitecan (SG) has already demonstrated significant advantages in advanced TNBC patients who failed multiple prior lines of therapy (ASCENT study). At a recent academic conference, Professor Carlos H. Barrios from the PUCRS School of Medicine in Porto Alegre, Brazil, presented the latest biomarker subgroup analysis from the ASCENT-03 study. This analysis deeply explored the differences in efficacy between SG and chemotherapy in the first-line setting across different Trop-2 expression levels, BRCA mutation statuses, and HER2 expression statuses. This article summarizes its core academic content to provide clinical physicians with a basis for decision-making in precision therapy.

In June 2026, China's National Medical Products Administration (NMPA) approved iza-bren (brand name: Yizekang®; generic name: Loncastuximab Eglonatamab), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) independently developed by Biokin Pharmaceutical. The approval is for the treatment of patients with relapsed or metastatic nasopharyngeal carcinoma (NPC) following prior therapy.

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Ciara Catherine O'Sullivan from Mayo Clinic, representing the I-SPY 2.2 collaborator group, announced the neoadjuvant treatment results of Rilvegostomig (an anti-PD-1/TIGIT bispecific antibody) combined with Trastuzumab Deruxtecan (T-DXd) for early-stage high-risk HER2-negative breast cancer. Based on innovative Response Predictive Subtypes (RPS), the study aims to improve the pathological complete response (pCR) rate through precise drug combinations and explore the possibility of reducing traditional cytotoxic chemotherapy.